#pfizer

All articles tagged with "pfizer"

Pfizer’s Monthly Obesity Drug Keeps Its Case Alive

New midstage data added to the case that Pfizer’s obesity drug, acquired from Metsera, may be suitable for monthly dosing.

Key Takeaways

Detailed midstage data offered further evidence for monthly dosing.
The obesity drug candidate entered Pfizer through its Metsera acquisition.

DT Editorial Team·Jun 7, 2026·via statnews.com

BioNTech, Pfizer Highlight Bispecific Cancer Data as FDA Upheaval Draws Scrutiny

At ASCO, BioNTech and Pfizer promoted new bispecific cancer data while senior FDA oncology official Rick Pazdur argued agency disruption could become a chance to rebuild.

Key Takeaways

ASCO coverage highlighted BioNTech and Pfizer bispecifics data.
Rick Pazdur said upheaval at the FDA could create a chance to restructure the agency.

DT Editorial Team·May 31, 2026·via statnews.com

Pfizer CEO Rules Out a Near-Term Mega-Merger

Pfizer chief executive Albert Bourla said “no” when asked whether the company would pursue a transformative merger or acquisition in the near or medium term, signaling a restrained stance on large-scale dealmaking.

Key Takeaways

Albert Bourla said Pfizer has no near- or medium-term mega-merger plans.
The comment came in response to a question on Pfizer’s earnings call.

DT Editorial Team·May 7, 2026·via endpoints.news

FDA clears Pfizer and Arvinas breast cancer drug, but uptake questions are already following it

The FDA has approved Pfizer and Arvinas’ vepdegestrant for a certain form of breast cancer, but the decision arrives with visible uncertainty about how broadly the drug will actually be used.

Key Takeaways

The FDA approved Pfizer and Arvinas’ vepdegestrant on May 1.
The approval covers patients with a certain form of breast cancer.

DT Editorial Team·May 2, 2026·via endpoints.news

Health

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.

DT Editorial Team·Mar 7, 2026·3 min read·via endpoints.news

#pfizer

Pfizer’s Monthly Obesity Drug Keeps Its Case Alive

BioNTech, Pfizer Highlight Bispecific Cancer Data as FDA Upheaval Draws Scrutiny

Pfizer CEO Rules Out a Near-Term Mega-Merger

FDA clears Pfizer and Arvinas breast cancer drug, but uptake questions are already following it

Pfizer’s Monthly Obesity Drug Keeps Its Case Alive

BioNTech, Pfizer Highlight Bispecific Cancer Data as FDA Upheaval Draws Scrutiny

Pfizer CEO Rules Out a Near-Term Mega-Merger

FDA clears Pfizer and Arvinas breast cancer drug, but uptake questions are already following it

Pfizer Secures Obesity Drug Approval in China